The effects of anagrelide on human megakaryocytopoiesis

British Journal of Haematology

Volumn 99, Issue 1, 1997, Pages 174-180

  Solberg Jr , Lawrence A ^a   Tefferi, Ayalew ^b   Oles, Karl J ^c   Tarach, Jerzy S ^b   Petitt, Robert M ^b   Forstrom, Lee A ^b   Silverstein, Murray N ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Digital imaging analysis; Glycoprotein IIb IIIa; Haemopoiesis; Megakaryocyte; Stem cells

Indexed keywords

ANAGRELIDE;

ADULT; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; COLONY FORMING UNIT M; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE LIFESPAN; THROMBOCYTHEMIA;

EID: 9844256082     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3503164.x     Document Type: Article

References (21)

1. Abe Andes, W, Noveck, R.J. & Fleming. J.S. (1984) Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thrombosis and Haemostasis, 52, 325-328.
2. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. American Journal of Medicine, 92, 69-76.
3. Balduini, C.L., Bertolino, G., Noris, P. & Ascari, E. (1992) Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haemotologica, 77, 40-43.
4. Bowie, E.J.W., Thompson J.H., Jr. Didisheim, P. & Owen, C.A., Jr (1971) Mayo Clinic Laboratory Manual of Hemostasis, p. 186. W. B. Saunders Company, Philadelphia.
5. Courtwright, W.E., Buchanan, J.O., Fleming, J.S. & Taylor, R. (1983) The effect of multiple oral doses of anagrelide on ADP and collagen-induced platelet aggregation in normal male subjects. (Abstract). American Society for Clinical Pharmacology and Therapeutics, 33, 220.
6. Dewanjee, M.K., Wahner, H.W., Dunn, W.L., Robertson, J.S., Offord, K.P., Fuster, V.D. & Chesebro, J.H. (1986) Comparison of three platelet markers for measurement of platelet survival time in healthy volunteers. Mayo Clinic Proceedings, 61, 327-336.
7. Gaver, R.C., Deeb, G., Pittman, K.A. & Smyth, R.D. (1981) Disposition of anagrelide, an inhibitor of platelet aggregation. Clinical Pharmacology and Therapeutics, 29, 381-386.
8. Gillespie, E. (1988) Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochemical Pharmacology, 37, 2866-2868.
9. Grant, B.W., Nichols, W.L., Solberg, L.A., Yachimiak, D.J. & Mann, K.G. (1987) Quantitation of human in vitro megakaryocytopoiesis by radioimmunoassay. Blood, 69, 1334-1339.
10. Kerns, E.H., Russell, J.W. & Gallo, D.G. (1987) Determination of anagrelide in plasma by capillary gas chromatography-mass spectrometry. Journal of Chromatography, 416, 357-364.
11. Leven, R.M. & Yee, M.K. (1987) Megakaryocyte morphogenesis stimulated in vitro by whole and partially fractionated thrombocytopenic plasma: a model system for the study of platelet formation. Blood, 69, 1046-1052.
12. Levine, R.F., Hazzard, K.C. & Lamberg, J.D. (1982) The significance of megakaryocyte size. Blood, 60, 1122-1131.
13. Li, C.Y., Ziesmer, S.C. & Lazcano-Villareal, O. (1987) Use of azide and hydrogen peroxide as an inhibitor for endogenous peroxidase in the immunoperoxidase method. Journal of Histochemistry and Cytochemistry 35, 1457-1460.
14. Mazur, E.M., Rosmarin, A.G., Sohl, P.A., Newton, J.L. & Narendran, A. (1992) Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood, 79, 1931-1937.
15. Mazzucconi, M.G., De Sanctis, V., Chistolini, A., Dragoni, F. & Mandelli, F. (1992) Therapy with anagrelide in patients affected by essential thrombocythaemia: preliminary results. Haematologica, 77, 315-317.
16. Silverstein, M.N., Petitt, R.M., Solberg, L.A., Jr, Fleming, J.S., Knight, R.C. & Schacter, L.P. (1988) Anagrelide: a new drug for treating thrombocytosis. New England Journal of Medicine, 318, 1292-1294.
17. Silverstein, M.N., Petrone, M.E., Petitt, R.M., Dement, M.P. & Vukovich, R.A. (1996) The safety profile of anagrelide for treatment of thrombocythemia. (Abstract). Blood, 88, (Suppl. 1), 583a.
18. Solberg, L.A., Jr, Jamal, N. & Messner, H.A. (1985) Characterization of human megakaryocytic colony formation in human plasma. Journal of Cellular Physiology, 124, 67-74.
19. Spencer, C.M. & Brogden, R.N. (1994) Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs, 47, 809-822.
20. m cyclic 3′,5′-adenosine monophosphate phosphodiesterase. Journal of Laboratory and Clinical Medicine, 95, 241-257.
21. Tefferi, A., Silverstein, M.N., Pet, R.M., Mesa, R.A. & Solberg, L.A., Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Seminars in Thrombosis and Hemostasis, in press.